At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically proven advanced non-squamous NSCLC; may be newly diagnosed, recurrent, progressive, or refractory (localized or widespread)
- ✓Measurable disease: at least one lesion ≥20 mm in longest diameter by CT/MR/PET, or ≥10 mm increase in previously irradiated areas
- ✓No chemotherapy for at least 4 weeks and no radiation to index lesion or clear progression in that lesion (>20% increase in longest diameter)
- ✓Life expectancy greater than 4 weeks
- ✕History of HIV or active infections
- ✕History of diabetes
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of the Effects of Dexamethasone on Non-Small Cell Lung Cancer Using [F-18] FLT for Imaging With Positron Emission Tomography (PET)
In Brief
A clinical study evaluating Dexamethasone, Device for PET, and 2 other interventions for Recurrent Non-Small Cell Lung Carcinoma and 3 related conditions. Completed, enrolled 6 participants across 1 site.
Detailed Summary
This pilot research trial studies the effects of dexamethasone in patients with non-small cell lung cancer that has not responded after previous treatment. Drugs such as dexamethasone can affect how tumors grow and respond to treatments. Imaging tests, such as fluoro-L-thymidine (FLT) positron emission tomography , use a small amount of radioactive substance to show changes in tumor cells. Studying the effects of dexamethasone on lung tumors using FLT positron emission tomography may help doctors plan better treatments.
Study Details
Timeline
Interventions
Given PO BID
Undergo 18F-FLT PET scan
Correlative studies
Undergo 18F-FLT PET scan